AJCP / Meeting AbstrActs three-or five-year intervals was simulated for 40 years (starting at age 30 years until age 70 years). Outcomes included invasive cervical cancer (ICC) cases, ICCrelated deaths, costs (2016 USD), and quality-adjusted life years (QALYs). Comprehensive sensitivity analyses were performed. Results: Model analyses predicted 40% fewer ICC cases with a three-year cotesting interval compared with a five-year interval (57.61 vs 96.51 per 10,000 women for three-and five-year intervals, respectively). ICC deaths were predicted to be 39% lower (23.06 vs 37.58 per 10,000 women for three-and five-year intervals, respectively). Results for the three-year interval screening show a lifetime gain of 0.0201 QALYs (23.0084 QALYs vs 22.9883 QALYs for three-and five-year intervals, respectively). The cumulative increase in screening costs for three-year cotesting intervals ($477 per woman over 40 years) was partially offset by cost savings ($114) realized from cervical cancer prevention and reduced treatment cost. The modest net increase in total cost for three-year co-testing intervals ($363) can be considered cost-effective compared with five-year cotesting based on an incremental cost-utility ratio (ΔCost/ΔQALY) of $18,060 per QALY gained. Conclusions: Cervical cancer cotesting at three-year intervals is predicted to be a cost-effective approach to reducing the number of ICC cases and ICC deaths over currently recommended five-year intervals. Introduction: Prostate-specific antigen (PSA) is the most commonly used cancer screening test in men. Currently, there are two sets of recommendations for PSA screening: one championed by the US Preventive Services Task Force against screening of men of all ages, and the other by the American Cancer Society for offering screening only to 50-to 69-year-old men after informed/shared decision making. We evaluated PSA screening rates from 2009 through 2015. Methods: Claims for PSA screening of asymptomatic men, done by excluding PSA testing associated with 62 prostate or urinary conditions, were collected using Medicare (17.7-21.8 million men >64 years old) and MarketScan (9.9-16.5 million men 30-64 years old) databases. Trend tests were performed using a two-sided Poisson regression with Bonferroni correction. Results: Annual PSA screening rates were 2% in men aged 30-39, 13%-14% in men aged 40-49, 29%-31% in men aged 50-59, 33%-36% in men aged 60-64, 9%-13% in men aged 65-69, 11%-15% in men aged 70-74, and 9%-13% in men aged ≥75 years. Downward temporal trends were significant for ages 60-64 years (P = .002) and 70-74 years (P = .004). The 2009 to 2015 change in screening rate ranged from a decrease of 16% in men aged 70-74 years to an increase of 2% in men aged 30-39 years. Overall, PSA screening has decreased. Conclusions: Despite all recommendations against screening men aged <50 and >69, PSA screening is still performed in these age groups. In the >49 age group, PSA screening rate decreased presumably due to combined influence of all recommendations. There is a need to further understand why consensus recommendations for screening of men <50 and >69 are not fully followed. These results might also suggest continued opportunities for laboratory professionals to work with clinicians to implement only evidenced-based laboratory screening recommendations.
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